Among genes involved in the RB dependent cell cycle regulatory cascade, the p16 tumor suppressor gene is frequently lost in the Ewing family of tumors

被引:104
作者
Kovar, H [1 ]
Jug, G [1 ]
Aryee, DNT [1 ]
Zoubek, A [1 ]
Ambros, P [1 ]
Gruber, B [1 ]
Windhager, R [1 ]
Gadner, H [1 ]
机构
[1] UNIV VIENNA, DEPT ORTHOPED, A-1090 VIENNA, AUSTRIA
基金
奥地利科学基金会;
关键词
Ewing tumors; p16; Rb; cyclin D; prognosis;
D O I
10.1038/sj.onc.1201397
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The pRB cell cycle regulatory cascade is frequently perturbed in neoplasia by overexpression of a component of the pRB-phosphorylating cyclin D1/CDK4 complex or by inactivation of pRB or the CDK4 inhibitors p16 and p15, We investigated the status and expression of p16, p15, CCND1, CDK4 and RE genes in the Ewing family of tumors, P16 loss was observed in 8 of 27 tumors (30%) and in 12 of 23 (52%) tumor cell lines from unrelated patients, There were no discrepancies in the p16 status between primary tumors and the corresponding cell lines and between cell Lines established from consecutive tumor samples, p15 was codeleted in most cases but p15 mRNA was absent also in cell lines retaining the gene, In addition, posttranscriptional p16 inactivation was observed in two cases, Although no evidence for CDK4 or CCND1 amplification was obtained, expression of these genes varied considerably in the cell lines in a case specific manner, In wild-type p16 cell lines, pRB expression was lost in one case, Our data indicate that, despite the absence of cytogenetically detectable 9p21 chromosomal aberrations, p16 deletions constitute the most frequent secondary molecular aberration in Ewing tumors so far, These results are discussed in the context of the stage of disease and the clinical outcome of the patients, The potential prognostic impact of these findings remains to be further evaluated.
引用
收藏
页码:2225 / 2232
页数:8
相关论文
共 41 条
[11]   Loss of the p16/MTS1 tumor suppressor gene causes E2F-mediated deregulation of essential enzymes of the DNA precursor metabolism [J].
Hengstschlager, M ;
Pusch, O ;
HengstschlagerOttnad, E ;
Ambros, PF ;
Bernaschek, G ;
Wawra, E .
DNA AND CELL BIOLOGY, 1996, 15 (01) :41-51
[12]  
HIRAMA T, 1995, BLOOD, V86, P841
[13]   P53 MUTATIONS IN HUMAN CANCERS [J].
HOLLSTEIN, M ;
SIDRANSKY, D ;
VOGELSTEIN, B ;
HARRIS, CC .
SCIENCE, 1991, 253 (5015) :49-53
[14]   Inactivation of p16(INK4) in hepatocellular carcinoma [J].
Hui, AM ;
Sakamoto, M ;
Kanai, Y ;
Ino, Y ;
Gotoh, M ;
Yokota, J ;
Hirohashi, S .
HEPATOLOGY, 1996, 24 (03) :575-579
[15]   PROLIFERATING CELL NUCLEAR ANTIGEN AND P21 ARE COMPONENTS OF MULTIPLE CELL-CYCLE KINASE COMPLEXES [J].
HUI, Z ;
YUE, X ;
BEACH, D .
MOLECULAR BIOLOGY OF THE CELL, 1993, 4 (09) :897-906
[16]  
JEN J, 1994, CANCER RES, V54, P6353
[17]   A CELL-CYCLE REGULATOR POTENTIALLY INVOLVED IN GENESIS OF MANY TUMOR TYPES [J].
KAMB, A ;
GRUIS, NA ;
WEAVERFELDHAUS, J ;
LIU, QY ;
HARSHMAN, K ;
TAVTIGIAN, SV ;
STOCKERT, E ;
DAY, RS ;
JOHNSON, BE ;
SKOLNICK, MH .
SCIENCE, 1994, 264 (5157) :436-440
[18]  
KHATIB ZA, 1993, CANCER RES, V53, P5535
[19]  
KOVAR H, 1993, ONCOGENE, V8, P2683
[20]  
Kovar H, 1996, CELL GROWTH DIFFER, V7, P429